Bevacizumab 联合吉西他滨对荷肝癌裸鼠移植瘤生长的抑制作用

目的:探讨抗血管生成药物Bevacizumab联合吉西他滨对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法:构建人肝癌细胞HepG2裸鼠皮下移植瘤模型,随机分为空白对照组、Bevacizumab组、吉西他滨组和联合用药组。观察用药前后肿瘤体积,绘制肿瘤生长曲线;应用免疫组化检测肿瘤微血管密度(MVD);Western Blot检测Bcl-2蛋白的表达。结果:Bevacizumab和吉西他滨单药均能抑制肿瘤生长,两药联合疗效明显增强(P=0.000)。与对照组和吉西他滨组相比,Bevacizumab组和联合用药组能明显抑制肿瘤血管生成,MVD值均明显降低,以联合用药组最为明显(P均0.000)。Bevacizumab和吉西他滨单药均能下调Bcl-2的表达,两药联合下调作用明显增强。结论:Bevacizumab联合吉西他滨能增强对人肝癌裸鼠移植瘤的生长及微血管生成的抑制作用,其机制可能与调控Bcl-2的表达有关。     

人结肠癌SW480细胞裸鼠皮下移植瘤DcR3基因的RNA干扰及其作用

目的:观察DcR3基因小干扰RNA(siRNA)对人结肠癌SW480细胞裸鼠皮下移植瘤DcR3基因表达的影响。方法:建立结肠癌SW480细胞裸鼠皮下移植瘤模型,瘤体注射脂质体与DcR3siRNA混合物,转染DcR3siRNA,免疫组织化学及RT-PCR检测观察DcR3基因的表达。结果:建立了结肠癌SW480细胞裸鼠皮下移植瘤模型;治疗后,治疗组移植瘤明显减小,空白对照组、阴性对照组肿瘤体积显著大于治疗组(P<0.01);各组肿瘤组织中DcR3基因均有不同程度的表达,治疗组表达程度明显低于阴性对照组及空白对照组(RT-PCRP<0.05,免疫组化P<0.01)。结论:人结肠癌SW480细胞在裸鼠皮下有良好的成瘤性;脂质体与DcR3siRNA混合物可特异性抑制结肠癌裸鼠皮下移植瘤内DcR3基因的表达。     

人肝细胞肝癌MHCC97H裸鼠移植模型的建立及索拉菲尼的药效研究

索拉菲尼是靶向血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)、B-Raf原癌基因(B-Raf proto-oncogene)等多种酪氨酸激酶的抑制剂,能有效延长晚期肝细胞肝癌(简称肝癌)患者的生存时间。该研究利用人肝癌细胞MHCC97H成功建立了裸鼠皮下异位移植模型以及原位移植模型,并评估了索拉菲尼对MHCC97H移植瘤的治疗作用。结果表明,MHCC97H可以在裸鼠皮下形成异位移植瘤,每天灌胃30 mg/kg索拉菲尼可显著抑制肿瘤生长。同时,MHCC97H也可以在裸鼠肝脏形成原位移植瘤。每天灌胃30 mg/kg索拉菲尼可以显著抑制裸鼠的血清甲胎蛋白(alpha fetoprotein,AFP)水平及原位瘤生长。综上所述,MHCC97H是构建皮下异位移植以及原位移植模型的一个理想肝癌细胞系,灌胃索拉菲尼在这两种移植瘤模型中都表现出显著的肿瘤抑制效果。     

酵母多糖对S_(180)荷瘤小鼠抗氧化作用和免疫机能的影响

目的:研究酵母多糖(zymosan)对S180荷瘤小鼠抗氧化状态和免疫功能的影响。方法:将昆明小鼠70只随机分为7组,第1组作为正常组,另6组将S180瘤细胞悬液接种于小鼠右前肢腋皮下制备荷瘤小鼠动物模型,分为zymosan低、中、高剂量组和环磷酰胺(Cy)组、肿瘤对照组及zymosan联合Cy治疗组,灌胃第7 d接种S180瘤,第19 d后测定小鼠肝匀浆中丙二醛(MDA)含量、谷胱甘肽过氧化酶(GSH-Px)和超氧化物歧化酶(SOD)活力,评价zymosan对小鼠抗氧化能力的作用。采用逆转录-聚合酶链反应(RT-PCR)检测IL-2、TNF-α、TGF-β1mRNA的表达,评价zymosan对小鼠免疫功能的影响。结果:zymosan各剂量组均能提高肝脏中GSH-Px活性和SOD活力,但zymosan高剂量组显著降低MDA水平(P<0.01)。zymosan各剂量组荷瘤小鼠肿瘤组织内TNF-α、IL-2 mRNA相对表达量明显高于Cy组和肿瘤对照组(P<0.01),同时下调TGF-β1水平。zymosan高剂量对小鼠S180瘤有明显抑制作用,且与Cy合用后有协同作用,并提高了小鼠的TNF-α、IL-2 mRNA的表达。结论:zymosan的抑瘤机制可能主要是抗氧化作用和免疫调节作用,且作用与剂量有关。     

人脐带间充质干细胞体内移植的安全性研究

目的:探讨人脐带间充质干细胞(hUCMSC)的成瘤性及其对荷瘤鼠肿瘤生长的影响。方法:分离培养hUCMSC,取第6代细胞裸鼠皮下移植,观察其成瘤性;对荷瘤鼠尾静脉注射移植hUCMSC,观察其对肿瘤生长的影响;体外共培养hUCMSC和MCF-7肿瘤细胞,观察hUCMSC对MCF-7细胞克隆形成率的影响。结果:hUCMSC裸鼠皮下移植30 d,未观察到有肿瘤形成;尾静脉注射移植hUCMSC对荷瘤鼠肿瘤的生长无明显影响;体外共培养结果表明,hUCMSC对MCF-7肿瘤细胞的克隆形成无明显影响。结论:hUCMSC体内移植无成瘤性;静脉移植后对肿瘤生长无显著影响。     

人血小板生成素cDNA转导抑制小鼠移植肉瘤(S180)的生长

以小鼠肉瘤S180为模型 ,研究人血小板生成素 (TPO)在肿瘤基因治疗方面的价值 .在小鼠接种瘤细胞前 2周 ,或在接种肿瘤细胞同时 ,给小鼠注射 10 0 μgTPO表达质粒 (pcDNA3 hTPO) ,在 2周和 4周时肿瘤平均重量明显小于单纯质粒 (pcDNA3)注射和生理盐水对照组 (提前转导组P <0 0 5 ,同时转导组P >0 0 5 ) .当肿瘤移植量为 1× 10 6时 ,2周时肿瘤的重量依次分别为 1 75 6g、3 6 37g和 3 92 6g ;当肿瘤移植量为 1× 10 5,2周时肿瘤的重量依次分别为 0 5 76g、5 6 1g和 5 84g .在转导基因 2周时 ,移植 1× 10 5肿瘤细胞组有 4 10受试鼠完全未形成肿瘤或肿瘤的生长被中止在早期阶段 .流式细胞分析发现 ,TPO转导后 ,肉瘤内浸润淋巴细胞从以CD8+为主转变为以CD4 +或CD4 +CD8+为主 .不过 ,TPO转导对瘤细胞在体外的增殖无明显改变 .TPO转导鼠的血清对S180细胞在体外的生长速度也无影响 .推测T淋巴细胞参与了TPO基因转导所产生的抗肿瘤作用     

表达血管抑制因子的腺相关病毒载体的构建及其体内外活性

血管抑制因子(Vasostatin,VAS),为集钙蛋白N-末端180个氨基酸大小的蛋白,是一种内源性血管生成抑制因子,对多种肿瘤的生长具有很强的抑制作用.近期有研究显示,VAS可以促进神经内分泌肿瘤的恶化,提醒研究人员在开发该抗肿瘤药物时必须非常谨慎.将VAS cDNA插入腺相关病毒-2表达质粒pAAV-2,采用无辅助病毒参与的三质粒共转染法制备rAAV-VAS病毒.体外分别转染小鼠胰内皮细胞MS1和结肠癌细胞HCT-116,MTT法测定对细胞生长的影响,Western blotting方法检测VAS的表述.采用小鼠皮下移植瘤模型,验证VAS的表达对肿瘤生长、新生血管密度、以及细胞增殖的作用.结果证明构建的rAAV-VAS病毒载体,能抑制小鼠胰内皮细胞的生长,转染HCT-116后能有效表达VAS蛋白,但HCT-116的体外生长不受影响.瘤体注射rAAV-VAS后,HCT-116移植瘤在小鼠体内的生长速度明显减缓,肿瘤新生血管密度明显降低.结果显示,rAAV-VAS可以抑制HCT-116移植瘤的新生血管形成,但对其细胞增殖无明显作用.     

一些抗癌药物对荷瘤小鼠血清中唾液酸含量的影响

测定荷六种小鼠肿瘤S180肉瘤(实体型和腹水型),腹水肝癌(HepA),艾氏腹水瘤(EC),白血病P388和Lewis肺癌的小鼠腹水和血清中唾液酸含量,结果显示血清中唾液酸含量与肿瘤生长、肿瘤类型有关。腹水中唾液酸含量高,推测肿瘤能比正常组织产生更多唾液酸。对四种腹水肿瘤用阴离子交换树脂层析鉴定,发现HepA腹水中葡萄糖代唾液酸(NcuGc)含量明显低于其它三种腹水瘤。还研究了十几种抗癌药物对荷S180和Lewis肺癌小鼠血清中唾液酸含量的影响。发现吗丙嗪(probimane)和顺铂(DDP)能降低荷瘤小鼠血清中唾液酸含量,提示此二药物在肿瘤治疗中更具选择性。     

小檗碱对急淋白血病的在体抗肿瘤及与Ara-C的联合作用研究

本实验旨在研究小檗碱(berberine, BBR)对急淋白血病细胞Jurkat的在体抗肿瘤作用及与阿糖胞苷(cytosine, Ara-C)的联合作用。本研究通过体外培养Jurkat细胞株,将细胞注射至裸鼠皮下,建立皮下移植瘤模型,待肿瘤体积长至约100 mm~3时,随机分为两组:对照组和小檗碱处理组,分别口服PBS、200 mg/kg小檗碱,隔天给药一次,隔天记录裸鼠体重及肿瘤体积大小。给药30 d后处死动物,剥离肿瘤组织,称量肿瘤大小,绘制肿瘤生长曲线、体重图及瘤重图,计算抑瘤率;采用免疫组化法检测移植瘤组织中细胞核增殖抗原Ki-67的表达水平。同时,本研究用一线用药阿糖胞苷(cytarabine, Ara-C)与小檗碱联合处理Jurkat细胞,研究两药联用的药效。发现小檗碱处理组移植瘤大小受到明显的抑制,瘤块组织中Ki-67的表达明显降低;Ara-C与小檗碱能协同抑制Jurkat细胞的增殖,联合指数(combination index, CI)1。本研究发现小檗碱能够抑制Jurkat细胞皮下移植瘤的增殖,在体内发挥抗急淋白血病活性,并能与一线用药Ara-C协同产生作用。     

shRNA靶向干扰COX-2抑制人肝癌裸鼠皮下移植瘤及其血管生成

目的:探讨重组干扰质粒pshRNA-COX-2对人肝癌细胞Hep3B裸鼠皮下移植瘤生长和肿瘤血管生成的抑制作用。方法:重组干扰质粒pshRNA-COX-2转染Hep3B细胞并筛选后,RT-PCR和Western blot检测COX-2mRNA和蛋白表达,RT-PCR检测VEGFmRNA表达。将被成功转染的Hep3B细胞种植于裸鼠皮下,测量肿瘤大小,4周后处死裸鼠,免疫组织化学法检测肿瘤组织中COX-2蛋白表达和肿瘤微血管密度(MVD)。结果:与未转染细胞相比,干扰组COX-2mRNA和蛋白表达抑制率分别为65.3%和52.8%(P<0.05),干扰组VEGFmRNA表达抑制率为56.5%(P<0.05)。干扰组瘤体大小明显小于阴性组和空白组(P<0.01)。干扰组COX-2得分和MVD均明显低于阴性组和空白组(P<0.01)。结论:pshRNA-COX-2通过抑制COX-2表达明显抑制人肝癌细胞Hep3B裸鼠皮下移植瘤生长和肿瘤血管生成。     

小鼠腹腔巨噬细胞被S-O_2-I菌苗激活后的抑瘤作用——Ⅱ.小鼠腹腔巨噬细胞被动转移的抑瘤效应及其肿瘤的病理观察

众所周知肿瘤的发展受宿主免疫功能的影响,当机体免疫功能下降时,肿瘤发展快,死亡率也高。卡介苗和厌氧棒状杆菌苗等一类的细菌佐剂能提高机体的免疫功能,增强机体对肿瘤细胞的排斥能力,它们的抗肿瘤活性和临床应用已有大量报道(Cross et al.,1976;Yamamura et al.,1979;Woodruff et al.,1975;Isral et al.,1976)。近年来,发现S-O_2-1菌苗在临床试用中,具有一定的抗肿瘤活性,并且副作用小,因     

Enhancing effects of mini-cells prepared from Salmonella typhimurium on anti-tumor immunity in sarcoma 180-bearing mice

Summary The enhancing effect of mini-cells of Salmonella typhimurium which do not contain chromosomal DNA on anti-tumor immunity in mice was studied. The growth of sarcoma 180 cells which were subcutaneously transplanted into ICR mice was significantly retarded in mice treated with Salmonella mini-cells at the same time or 7 days after S180 transplantation, while no or only a little growth inhibition was observed in mice treated 7 days prior to S180 transplantation. Treatment with mini-cells inoculation alone did not increase the survival time of mice that had received intraperitoneal transplants of S180 cells. However, a statistically significant increase of survival time was observed in mice treated with a combination of mini-cells and surgical resection of subcutaneous tumors when S180 cells were injected 7 days after the surgical resection. The injection of mini-cells restored macrophage chemotaxis in S180-bearing mice in which macrophage chemotaxis was greatly retarded but lymphocyte activity was not.     

Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity

Our laboratory has previously developed a tumor-targeting double-auxotrophic mutant of Salmonella typhimurium termed A1-R. The present report demonstrates that S. typhimurium A1-R destroys tumor blood vessels and this is enhanced in tumors with high vascularity. Red fluorescent protein (RFP)-expressing Lewis lung cancer cells (LLC-RFP) were transplanted subcutaneously in the ear, back skin, and footpad of nestin-driven green fluorescent protein (ND-GFP) transgenic nude mice, which selectively express GFP in nascent blood vessels. Color-coded in vivo imaging demonstrated that the LLC-RFP ear tumor had the highest cell density and the footpad tumor had the least with the ear tumor having more abundant blood vessels than that on the back or footpad. The tumor-bearing mice were treated with A1-R bacteria via tail-vein injection. Tumors in the ear were the earliest responders to bacterial therapy and hemorrhaged severely the day after A1-R administration. Tumors growing in the back were the second fastest responders to bacterial treatment and appeared necrotic 3 days after A1-R administration. Tumors growing in the footpad had the least vascularity and were the last responders to A1-R. Therefore, tumor vascularity correlated positively with tumor efficacy of A1-R. The present study suggests that bacteria efficacy on tumors involved vessel destruction which depends on the extent of vascularity of the tumor.     

Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity

Our laboratory has previously developed a tumor-targeting double-auxotrophic mutant of Salmonella typhimurium termed A1-R. The present report demonstrates that S. typhimurium A1-R destroys tumor blood vessels and this is enhanced in tumors with high vascularity. Red fluorescent protein (RFP)-expressing Lewis lung cancer cells (LLC-RFP) were transplanted subcutaneously in the ear, back skin and footpad of nestin-driven green fluorescent protein (ND-GFP) transgenic nude mice, which selectively express GFP in nascent blood vessels. Color-coded in vivo imaging demonstrated that the LLC-RFP ear tumor had the highest cell density and the footpad tumor had the least. The ear tumor had more abundant blood vessels than that on the back or footpad. The tumor-bearing mice were treated with A1-R bacteria via tail-vein injection. Tumors in the ear were the earliest responders to bacterial therapy and hemorrhaged severely the day after A1-R administration. Tumors growing in the back were the second fastest responders to bacterial treatment and appeared necrotic 3 days after A1-R administration. Tumors growing in the footpad had the least vascularity and were the last responders to A1-R. Therefore, tumor vascularity correlated positively with tumor efficacy of A1-R. The present study suggests that bacteria efficacy on tumors involves vessel destruction which depends on the extent of vascularity of the tumor.Key words: tumor targeting bacteria, Salmonella typhimurium A1-R, Lewis lung carcinoma, RFP, GFP, nestin, nude mice     

Allosensitization induced suppression of various murine tumors: role of non-H-2 antigens in antitumor immunity

Presence of alloantigens on various murine tumors was tested by tumor rejection in allosensitized Swiss mice. The results indicated the presence of alloantigen on immunogenic tumors like chemically induced fibrosarcoma (FS), ascitic sarcoma 180 (S 180) and immunogenic variant of lymphosarcoma (LS-A) in Swiss mice, while these antigens could not be detected by this procedure on spontaneous lymphosarcoma (LS). Allosensitization with skin graft was found to offer quantitatively higher antitumor resistance than the allosensitization achieved by allogeneic lymphocytes. Antitumor effect was not seen when tumor cells were inoculated earlier than day 3 of grafting. Further, host immunosuppression with whole body irradiation up to day of 3 of skin grafting abrogated the antitumor effect. H-2 compatible and non-H-2 incompatible skin graft sensitization of host could offer resistance against both S 180 and LS-A. Further, tumor immune mice rejected H-2 compatible, non-H-2 incompatible skin graft significantly earlier.     

Manganese superoxide dismutase expressed in silkworm larvae,Bombyx mori L enhances the NK activity and splenocyte proliferation against Sarcoma 180 tumor cells in vivo

Natural killer cell (NK) is known as a major immune system in body through mediating cell death via several possible pathways, and one of three subpopulations of lymphocytes functioning as scavenger of tumor, virus infected cells etc. Our present results found that the SOD-contained silkworm larvae powder caused an enhancement of the effect on NK cell cytotoxicity, which implied this material modulated the immune system in mice in vivo. The NK cell activities of S180 tumor modeled mice treated with silkworm powder including SOD were enhanced significantly ranging from 30% to 48%, respectively, compare to a distilled water feeding control and silkworm powder without SOD. Meanwhile, the ConA-stimulated splenocyte proliferation of all three treated groups was higher than that of the control both in T cells or B cells. The average tumor weight of S180 modeled mice treated with doses of SOD-contained silkworm powder was lighter than that of water control showing the tumor inhibition rates (IR) reached to 22.51% to 37%, respectively. In conclusion, these findings demonstrate that administration of silkworm larvae powder containing SOD results in activation of NK cells and immune T-cell and B-cell, suggesting the silkworm larvae powder containing SOD play a positive role in tumor inhibition.     

Antineoplastic effects of carnosine and beta-alanine--physiological considerations of its antineoplastic effects

Antineoplastic effects of carnosine (CAR) and beta-alanine (ALA), were examined in vivo using ddY mice implanted with the solid tumor Sarcoma-180. The sarcoma was treated with trypsin, 10(5) cells were implanted subcutaneously in the back of the animals, and CAR and ALA were administered subcutaneously 2 cm from the implantation site starting on the next day. The animals treated with ALA alone showed prolongation of survival to a T/C value of 132%; the growth of the tumor was inhibited and mortality reduced in those treated with CAR alone. Regression of the tumor was observed in the animals treated with either drug. The effects of these agents were enhanced when administered in combination with the non-specific active immuno-enhancing agent OK-432. More than half the animals treated with CAR and OK-432 survived the observation period (T/C greater than 218%), and survival was prolonged in those treated with ALA and OK-432 to a T/C value of 132%. The agents also showed potent antineoplastic effects on Sarcoma-180 when the tumor had been attenuated in vivo with mitomycin C (MMC).     

小鼠腹腔巨噬细胞被S-O_2—1激活后的抑瘤作用 Ⅰ.小鼠腹腔巨噬细胞的体外细胞毒作用及扫描电镜观察

在六十年代Mathe就用卡介苗来治疗小儿白血病,并获得了良好的效果。以后人们开始重视如何利用微生物佐剂刺激机体的防御机制,增强机体对肿瘤的排斥能力,来达到提高肿瘤治疗效果的目的。     

Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers

1-(3-1,2,4-Nitrotriazole-1-yl)-propanhydroxyiminoamide and 1-(6-nitrobenzoimidazole-1-yl)-propanhydroxyiminoamide were synthesized and radiolabeled with (99m)Tc. The (99m)Tc labeled complexes continuously accumulated in hypoxic murine sarcoma S180 cells in vitro but not in aerobic cells. Biodistribution results in mice bearing S180 tumor indicated that the tracers could localize in tumor and eliminate from it slowly. These results suggested that the (99m)Tc labeled nitrobenzoimidazole and nitrotriazole might be the novel tumor hypoxia markers.     

小鼠S_(180)瘤细胞免疫性的初步研究

本文选用灵敏度高,特异性强的酶标免疫吸附测定法(ELISA)及A.D.C.C.测试法(Antibody Dependent Cell mediated Cytotoxicity Assay)检测到以S_(180)瘤细胞免疫的小鼠血清中有抗S_(180)瘤细胞的特异抗体。并初步探讨了S_(180)肿瘤细胞膜上的唾液酸与抗原抗体相互作用的关系。实验表明S_(180)肿瘤细胞经唾液酸酶作用,水解去除瘤细胞表面的唾液酸后,对其与特异抗体的结合反应无明显影响。这提示S_(180)瘤细胞膜表面的糖蛋白上的唾液酸未必直接参与抗原抗体的特异性结合。以上结果为进一步研究患瘤小鼠各阶段的免疫情况及寻求最佳免疫时机,为治疗肿瘤奠定了基础。